LFG
SYRE icon

Larson Financial Group’s Spyre Therapeutics SYRE Stock Holding History

Larson Financial Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.59K Buy
63
+27
+75% +$1.97K ﹤0.01% 2720
2026
Q1 		$1.82K Sell
36
-108
-75% -$4.07K ﹤0.01% 2989
2025
Q4 		$4.72K Buy
144
+132
+1,100% +$3.45K ﹤0.01% 2483
2025
Q3 		$201 Buy
12
+6
+100% +$98 ﹤0.01% 3262
2025
Q2 		$90 Sell
6
-38
-86% -$562 ﹤0.01% 3177
2025
Q1 		$710 Buy
+44
New +$915 ﹤0.01% 2484

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Larson Financial Group's SYRE Position: Q2 2026 in Review

Larson Financial Group increased its Spyre Therapeutics (SYRE) stake by 75% in Q2 2026, buying an estimated $1.97K and bringing the position to 63 shares worth $5.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Larson Financial Group first reported a position in SYRE in Q1 2025 and has held it in 6 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Larson Financial Group held 63 shares of Spyre Therapeutics worth $5.59K as of Q2 2026.
  • Larson Financial Group bought 27 Spyre Therapeutics shares in Q2 2026, an estimated $1.97K.
  • Spyre Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2720 holding.
  • Larson Financial Group first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.